OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
25
Results
Show all
Save search
Copy query
Show results for
Unknown
(25)
Publication Date
Release Date
2021
(5)
2022
(4)
2018
(3)
2023
(2)
2015
(2)
2013
(2)
2012
(2)
2025
(1)
2016
(1)
2014
(1)
2011
(1)
2010
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology.
Not available
S-EPMC4979242
|
biostudies-literature
Cite
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
Not available
S-EPMC3691356
|
biostudies-literature
Cite
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
Not available
S-EPMC4105484
|
biostudies-literature
Cite
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Not available
S-EPMC4980567
|
biostudies-literature
Cite
High light and temperature reduce photosynthetic efficiency through different mechanisms in the C
4
model Setaria viridis.
Not available
S-EPMC8446033
|
biostudies-literature
Cite
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Not available
S-EPMC4268249
|
biostudies-literature
Cite
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
Not available
S-EPMC3494835
|
biostudies-literature
Cite
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Not available
S-EPMC3139394
|
biostudies-literature
Cite
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
Not available
S-EPMC3434983
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets